US stock futures flounder amid tech weakness, Fed caution
Tandem Diabetes Care (NASDAQ:TNDM) Inc’s stock has reached a new 52-week low, trading at 14.86 USD, down significantly from its 52-week high of 47.60 USD. This milestone comes amidst a challenging year for the company, with InvestingPro data showing a steep decline of 63.96% over the past year. The company’s current market capitalization stands at approximately $993 million. The stock’s decline over the past year underscores the hurdles faced by the company in navigating market conditions and operational challenges, with a concerning negative EBITDA of -$75 million. As investors assess Tandem Diabetes Care’s current position and future prospects, this 52-week low marks a critical point in the company’s recent trading history. InvestingPro analysis reveals 8 additional key insights about the company’s financial health and market position, available to subscribers along with a comprehensive Pro Research Report.
In other recent news, Tandem Diabetes Care reported its Q1 2025 earnings, revealing a revenue of $234 million, which represents a 22% year-over-year increase and exceeded forecasts. However, the company posted an EPS of -1.97, significantly missing the forecast of -0.6. Canaccord Genuity responded by raising Tandem’s price target to $59, citing strong quarterly performance and revenue growth in both U.S. and international markets. Meanwhile, Citi downgraded Tandem to Sell from Neutral, expressing concerns over competitive pressures and potential pricing challenges. Truist Securities initiated coverage with a Hold rating, noting Tandem’s position in the market despite share loss and below-peer growth. Additionally, Tandem received FDA clearance for its SteadiSet Infusion Set, designed for use up to three days, as part of its ongoing efforts to enhance diabetes management solutions. The company plans to seek further FDA approval for extended use of the SteadiSet to seven days. These developments highlight a mix of positive growth indicators and challenges facing Tandem Diabetes Care in the competitive medical device market.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.